Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Lingo

Neurological Surgery Savannah, GA Medical Doctor

NPI 1427294727 CMS profile 4602352

4 E Jackson Blvd, Savannah, GA 31405

Open in the dashboard

General payments

$3,499

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Lingo of Savannah, GA is reported in the CMS Open Payments database as having received $3,499 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $373 17
2024 General $415 14
2023 General $475 16
2022 General $549 16
2021 General $732 16
2020 General $189 7
2019 General $767 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Lingo
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Patrick Lingo were reported at $373. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Patrick Lingo Neurological Surgery median Middle half National median
2019 $767 $582 $138–$3,006 $163
2020 $189 $294 $76–$2,174 $114
2021 $732 $387 $105–$2,432 $132
2022 $549 $542 $139–$2,989 $149
2023 $475 $534 $145–$2,697 $160
2024 $415 $574 $155–$3,046 $164
2025 $373 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $754 29 payments
  2. Medtronic USA, Inc. $599 17 payments
  3. Abbott Laboratories $480 16 payments
  4. GT Medical Technologies, Inc $402 1 payment
  5. Medtronic, Inc. $224 7 payments
  6. Stryker Corporation $152 4 payments
  7. NuVasive, Inc. $116 3 payments
  8. Arbor Pharmaceuticals, Inc. $93 12 payments
  9. Cerapedics, Inc. $82 1 payment
  10. Novocure Inc. $68 3 payments
  11. Other $529 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,464 111 payments
  2. Education $35 8 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $496 16 payments
  2. GammaTile $402 1 payment
  3. ACTIVA $232 6 payments
  4. PROCLAIM $217 6 payments
  5. PIVOX Oblique Lateral Spinal System $156 2 payments
  6. Proclaim IPG $134 2 payments
  7. VITOSS $104 1 payment
  8. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $82 1 payment
  9. XLIF $80 1 payment
  10. nanoLOCK-L $76 1 payment
  11. Other $1,694 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

516

Median for Neurosurgery: 83

Drug cost

$3,199

Median for Neurosurgery: $872

Branded share of claims

25.8%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 117 $971
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 91 $739
Methylprednisolone Generic 64 $339
Gabapentin Generic 43 $322
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 42 $275
Meloxicam Generic 80 $216
Cyclobenzaprine Hcl Generic 30 $204
Tramadol Hcl Generic 36 $124
Diazepam Generic 13 $10

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$167,991

Of which drugs: $337

Medicare patients

278

Average age 74

Services billed

2,524

161 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Chronic kidney disease 29%
Ischemic heart disease 28%
Depression 28%
Heart failure 21%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadobutrol, 0.1 ml A9585 Office 16 1,401 $337

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record